TABLE 1.
Prevalence and Age of Onset of life-time and 12-month MDE, by Gender. The ESEMeD-Spain project.
| Total | Females | Males | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Diagnosi s (12 Mo or LT) |
Cohorts | Denominator N1 | N2 | %(SE) | Denominator N1 |
N2 | %(SE) | Denominator N1 |
N2 | %(SE) | 1 df test between gender3 |
| 12-month MDE |
18–34 | 1567 | 61 | 3.6 (0.7) | 834 | 46 | 5.2 (1.1) | 733 | 15 | 1.9 (0.6) | X2=7.5*, P=.006, df=1 |
| 35–49 | 1431 | 62 | 3.8 (0.5) | 809 | 44 | 4.8 (0.8) | 622 | 18 | 2.7 (0.5) | X2=4.4*, P=.035, df=1 |
|
| 50–64 | 1024 | 66 | 5.4 (0.7) | 587 | 50 | 7.8 (1.2) | 437 | 16 | 2.9 (0.8) | X2=9.7*, P=.002, df=1 |
|
| 65+ | 1451 | 58 | 3.6 (0.6) | 822 | 51 | 5.4 (0.9) | 629 | 7 | 0.9 (0.4) | X2=15.9*, P=.000, df=1 |
|
| All Ages | 5473 | 247 | 4.0 (0.3) | 3052 | 191 | 5.7 (0.5) | 2421 | 56 | 2.2 (0.3) | X2=31.2*, P=.000, df=1 |
|
| 3 df significance test across cohorts3 |
. | . | X2=6.5, P=091, df=3 |
. | . | X2=3.9, P=.274, df=3 |
. | . | X2=11.4*, P=010, df=3 |
-- | |
| LT MDE | 18–34 | 1567 | 167 | 9.1 (0.8) | 834 | 114 | 12.3 (1.3) | 733 | 53 | 6.0 (1.0) | X2=14.2*, P=.000, df=1 |
| 35–49 | 1431 | 194 | 11.9 (0.8) | 809 | 141 | 15.3 (1.5) | 622 | 53 | 8.3 (1.2) | X2=10.9*, P=.001, df=1 |
|
| 50–64 | 1024 | 160 | 12.6 (1.0) | 587 | 118 | 17.9 (1.8) | 437 | 42 | 6.9 (1.3) | X2=21.1*, P=.000, df=1 |
|
| 65+ | 1451 | 151 | 9.8 (1.0) | 822 | 125 | 14.0 (1.7) | 629 | 26 | 4.0 (0.8) | X2=21.9*, P=.000, df=1 |
|
| All Ages | 5473 | 672 | 10.6 (0.5) | 3052 | 498 | 14.5 (0.8) | 2421 | 17 4 |
6.4 (0.5) | X2=55.9*, P=.000, df=1 |
|
| 3 df significance test across cohorts3 |
. | . | X2=10.9*, P=012, df=3 |
. | . | X2=8.5*, P=.037, df=3 |
. | . | X2=7.5, P=.058, df=3 |
-- | |
| 12-month MDE among LT MDE |
18–34 | 167 | 61 | 39.2 (5.5) | 114 | 46 | 42.5 (6.5) | 53 | 15 | 32.6 (8.8) | X2=0.8, P=363, df=1 |
| 35–49 | 194 | 62 | 31.9 (3.7) | 141 | 44 | 31.4 (4.7) | 53 | 18 | 32.9 (5.1) | X2=0.1, P=.816, df=1 |
|
| 50–64 | 160 | 66 | 43.3 (4.0) | 118 | 50 | 43.7 (5.2) | 42 | 16 | 42.1 (8.7) | X2=0.0, P=.887, df=1 |
|
| 65+ | 151 | 58 | 36.2 (3.9) | 125 | 51 | 38.8 (4.4) | 26 | 7 | 23.7 (8.7) | X2=2.2, P=.142, df=1 |
|
| All Ages | 672 | 247 | 37.5 (1.9) | 498 | 191 | 39.0 (2.3) | 174 | 56 | 33.7 (3.9) | X2=1.2, P=.281, df=1 |
|
| 3 df significance test across cohorts3 |
. | . | X2=3.1, P=.376, df=3 |
. | . | X2=3.4, P=.336, df=3 |
. | . | X2=2.9, P=.401, df=3 |
-- | |
| Median Age of Onset (IQR Range) |
18–34 | 167 | 19.2 (16.8–23.8) |
114 | 19.0 (16.1–23.7) |
53 | 19.7 (17.4–23.9) |
X2=0.2, P=.636, df=1 |
|||
| 35–49 | 194 | 31.1 (23.4–37.0) |
141 | 32.0 (23.9–37.0) |
53 | 29.7 (22.1–36.9) |
X2=0.0, P=.856, df=1 |
||||
| 50–64 | 160 | 44.5 (33.8–49.9) |
118 | 44.3 (33.3–49.0) |
42 | 46.9 (35.1–51.6) |
X2=0.2, P=.643, df=1 |
||||
| 65+ | 151 | 52.8 (34.9–62.7) |
125 | 50.0 (34.8–62.0) |
26 | 54.5 (26.7–63.7) |
X2=0.0, P=876, df=1 |
||||
| All Ages | 672 | 30.0 (19.7–44.3) |
498 | 32.0 (19.8–45.0) |
17 4 |
28.9 (19.3–39.5) |
X2=2.3, P=.127, df=1 |
||||
1
Total cases among each age group
2
cases of 12-mo/LT MDE among the age groups
3
3 df tests for significant difference across age groups and 1 df test for significance difference across genders; odds ratios and significance tests are not presented for the models where the size of the subsample is less than 15, or the count of the dependent variable is less than 5
*
Significant at the 0.05 level